Hals-Nasen-Ohren-Heilkunde
Internationale klinische Evidenz zur Hirudotherapie bei Hörverlust, Sinusitis und HNO-Erkrankungen
Ear replantation falls inside the K040187 FDA-cleared device indication; sinusitis, vasomotor rhinitis, and hearing loss are off-label. For tier-based clinical reasoning, see Clinical Knowledge Support.
Off-Label-Anwendung — für diese Indikation nicht FDA-zugelassen
Zugelassene Indikation: Otolaryngologic applications (sinusitis, hearing loss, vasomotor rhinitis, peritonsillar abscess)
Off-Label-Verordnungen sind in den Vereinigten Staaten zulässig und bleiben eine klinische Entscheidung. Die folgende Erörterung dient dem Bildungskontext und stellt keine FDA-zugelassene Indikation dar.
Experimentelle Anwendung
Internationale klinische Evidenz
The middle ear, paranasal sinuses, and cochlea share end-arterial blood supply, narrow drainage, and fractional-millimeter tolerance for edema. ENT hirudotherapy is documented across 259+ patients in seven investigations (1935-2003): chronic SNHL (n=104), sinusitis (n=60), vasomotor rhinitis (n=55), cochleovestibular disorders (n=40), and inflammatory ear disease. No randomized controlled trial exists for any ENT indication.
Biologische Begründung
Mikrozirkulation und entzündungshemmend
Histamine-like vasodilator increases periauricular/paranasal capillary flow. Hyaluronidase facilitates lymphatic drainage. Eglins block elastase/cathepsin G; LDTI attenuates mast cell mucosal inflammation; C1s complement inhibitor modulates classical pathway — relevant to sinusitis and neuritis.
Antikoagulans und Lipid
Hirudin prevents fibrinogen clotting. Calin/saratin inhibit platelet adhesion. Destabilase-M lyses fibrin. Lipase and cholesterol esterase reduce circulating lipids. Together these target cochlear ischemia from vertebrobasilar atherosclerosis.
Klinische Evidenz
GRADE-Evidenzniveau: Niedrig
Beobachtungsstudien oder RCTs mit erheblichen Einschränkungen
| Studie | Design | Population (n=) | Intervention | Primäres Outcome | Ergebnis |
|---|---|---|---|---|---|
| Seleznev & Shchetinina 1990 | Protocol guidelines + case series | Neuritis, tinnitus, otitis, trigeminal neuralgia (n=NR) | 1-5 leeches; 2-9 sessions; mastoid, tragus, application sites | Pain, audiometric noise, electroconductivity | Pain resolved 1-2 sessions; decreased tinnitus; shortened disability In Baskova et al. guidelines; n not reported; Level IV |
| Grigoryev et al. 1998 | Case series | Chronic otitis media with vascular comorbidity (n=NR) | Leeches to vertebrobasilar region | Blood biochemistry, neurological symptoms | Hypercoagulable profile corrected; neurological symptoms resolved Vascular comorbidity mimicking otogenic complications; Level IV |
| Grigoryev & Krymskaya 1998 | Case series | Cochleovestibular disorders, peripheral origin (n=40) | Mastoid application sites; 15-20 min exposure | Tinnitus, head heaviness | All 40: reduced tinnitus; subjective lightness in head Vascular etiology; bleeding up to 5h; Level IV |
| Zhuravsky 2000 | Prospective cohort (doctoral thesis) | Chronic SNHL: vascular, neurogenic, presbycusic, ototoxic (n=104) | 1-4 leeches; 25-30 weekly sessions; 8-site rotation | Audiometry, speech comprehension, histology (animal) | Audiometric gain (vascular); speech comprehension (presbycusis); stabilization (ototoxic) Largest ENT study; preclinical histologic data; Level IV |
| Moskalenko 2001 | Case series | Acute sinusitis (n=60) | Endonasal bilateral; 1-5 sessions; 2-10 leeches total | Headache, sinus puncture avoidance, antibiotics | Headache reduced; sinus puncture avoided; antibiotics eliminated Clinically significant procedural sparing; Level IV |
| Krymskaya et al. 2003 | Prospective cohort | Vasomotor rhinitis: idiopathic (20), drug-induced (35) (n=55) | Endonasal via syringe device; 2-6 sessions q2-3d | Nasal breathing, medication need; 3-4 month follow-up | Immediate breathing restoration; 3/55 required medication at follow-up AE: septal hematoma 1.8%, allergic rhinorrhea 9.1%; Level IV |
| Zhuravsky 2000 | Animal histologic study (preclinical) | Membranous labyrinth (animal model) (n=NR) | Hirudotherapy in experimental animals | Hair cell activity, capillary density, neuroepithelium | Enhanced hair cells; increased stria vascularis capillaries; neuroprotection Structural basis for audiometric improvements; preclinical |
Entzündliche Ohrerkrankung — Protokoll Seleznev und Shchetinina (1990)
| Indikation | Blutegel | Sitzungen | Platzierung | Expositionszeit |
|---|---|---|---|---|
| Acute auditory nerve neuritis | 1-3/side | 5-9 | Mastoid, 1 cm from auricle; bilateral | Full engorgement |
| Tinnitus (chronic neuritis) | 1-3 | 5-9 | Acupuncture points, affected side | 3-5 min |
| Acute external otitis | 1-3 | 2-4 | Mastoid; tragus; inflammation site | 5-7 min |
| Non-perforative otitis media | 2-5 | 2-4 | Mastoid; tragus | 3-5 min |
| Adhesive otitis media | 2-5 | 4-7 | Mastoid; tragus | 3-5 min |
| Secondary trigeminal neuralgia | 1-3 | 2-4 | Trigeminal nerve exit points | 3-5 min |
Pain resolved after 1-2 sessions in most cases. Audiometric testing showed decreased tinnitus intensity, skin electroconductivity increased, tissue oxygenation rose, and disability duration shortened.
Chronischer sensorineuraler Hörverlust — Zhuravsky (2000), n=104
The largest ENT hirudotherapy study examined 104 patients with chronic SNHL using an 8-site rotation protocol (25-30 weekly sessions, 1-4 leeches each). Outcomes varied by etiology:
Vaskulär/neurogen
Audiometric threshold improvement. SGS anticoagulant/vasodilatory actions directly target cochlear ischemia from vertebrobasilar compromise. Strongest etiologic response.
Presbyakusis
Improved speech comprehension without pure-tone threshold change — central neurovascular processing benefit rather than peripheral hair cell recovery.
Sekundär (Mittelohr)
Reduction in both conductive and sensorineural components — combined mechanism via decongestion and microvascular improvement.
Ototoxisch/postinfektiös
Nonspecific stabilization of remaining function — neuroprotective rather than regenerative effect.
Kochleovestibuläre Störungen
Grigoryev und Krymskaya (1998) — n=40
Peripheral cochleovestibular disorders with vascular etiology (hypertension, atherosclerosis). Elevated cholesterol, beta-lipoproteins, fibrinogen; shortened clotting time. Leeches on mastoid application sites, 15-20 min. All 40 patients: reduced tinnitus, subjective head lightness, corrected hypercoagulable profile.
Akute Sinusitis
Moskalenko (2001) — n=60
Endonasal bilateral application; full engorgement; 1-5 sessions; 2-10 leeches total. Near-universal headache reduction. Treatment shortened. Maxillary sinus puncture avoided — eliminating an invasive procedure with orbital/intracranial complication risk. Antibiotic courses eliminated. This represents a substantial reduction in procedural burden: sinus puncture/lavage is the standard Russian ENT intervention for refractory acute sinusitis.
Vasomotorische Rhinitis
Krymskaya et al. (2003) conducted the most detailed endonasal study: 55 patients — 20 idiopathic, 35 drug-induced (rhinitis medicamentosa); 25/35 on antihypertensives. All underwent pre-treatment sinus probing/lavage to exclude purulent disease. Endonasal application to anterosuperior nasal septum via syringe containment device; 2-6 sessions at 2-3 day intervals.
Ergebnisse
- Immediate: Improvement or complete restoration of nasal breathing; disappearance of head heaviness; resolution of ear congestion
- 3-4 month follow-up: Only 3/55 patients required medication — remarkable reduction in drug dependence
- Pain: No patient reported procedural pain (0/55)
Unerwünschte Ereignisse
- Septal hematoma: 1/55 (1.8%) — premature mucocapillary closure; requires prompt drainage
- Allergic rhinorrhea: 5/55 (9.1%) — managed with antihistamines; treatment continued
- 9.1% allergic rate is higher than 2-5% cutaneous, possibly from nasal mucosal immunoreactivity
Klinisches Protokoll
Patientenauswahl und Vor-Verfahren
Candidates include patients with otitis, auditory neuritis/tinnitus, chronic SNHL (vascular/neurogenic/presbycusic), acute sinusitis, vasomotor rhinitis, and cochleovestibular disorders with vascular comorbidity. All patients must receive concurrent standard ENT care. Pre-procedure workup: audiometry for hearing indications; sinus probing/lavage to exclude purulent sinusitis (mandatory before endonasal application); blood biochemistry (cholesterol, fibrinogen, prothrombin index); coagulation panel; vertebrobasilar Doppler for vascular etiology; medication review.
| Parameter | Otitis / Neuritis | Chronischer SNHL | Sinusitis | Rhinitis |
|---|---|---|---|---|
| Stelle | Mastoid, 1 cm from auricle | 8-site rotation | Nasal septum bilateral | Nasal septum anterosuperior |
| Leeches | 1-5/session | 1-4/session | 2-10 total | 1-2/session |
| Sessions | 2-9; q2-3d | 25-30; weekly | 1-5; q2d | 2-6; q2-3d |
| Exposure | 3-7 min or full | Full engorgement | Full engorgement | Full engorgement |
Zhuravsky 8-Stellen-Rotation (chronischer SNHL)
- Posterior neck paravertebral (1-2 cm from spinous processes)
- Mastoid processes
- External auditory canal (cartilaginous portion)
- Scalp posterior to mastoid
- Nasal vestibule (skin-mucosa junction)
- Carotid artery projection (mid anterior neck)
- Sacrum (reflex — systemic hemodynamics)
- Right hypochondrium (reflex — hepatic clearance)
Endonasale Technik
- Containment: 2-mL syringe (plunger/tip removed) as hollow cylinder
- Site: Anterosuperior nasal septum
- Bilateral: Both nares simultaneously
- Position: Seated, head tilted back; continuous monitoring
- Post-procedure: Monitor for septal hematoma (24-48h) and rhinorrhea
Nach dem Eingriff
Sterile dressing (expect oozing up to 5h periauricular). Audiometric follow-up at course completion. Repeat sinus lavage for obstruction assessment. Blood biochemistry for vascular patients. Nasal septum check at 24-48h post-endonasal. Vasomotor rhinitis: 3-4 month reassessment.
Sicherheitsüberlegungen
- Endonasal bleeding: Kiesselbach plexus = prolonged bleeding. Nasal packing must be available. Contraindicated with anticoagulants without risk-benefit assessment
- Septal hematoma: 1/55 (1.8%); requires prompt drainage to prevent abscess, cartilage necrosis, saddle-nose deformity
- Leech migration (nasal): Aspiration hazard if leech reaches nasopharynx. Syringe containment + continuous monitoring mandatory
- Leech migration (ear canal): Limit to lateral cartilaginous canal; continuous visual monitoring to prevent tympanic membrane contact
- Allergic rate: 9.1% endonasal vs 2-5% cutaneous; manage with antihistamines
- Infection: Aeromonas hydrophila — nasal cavity proximity to sinuses/cavernous sinus. Prophylactic fluoroquinolone or TMP-SMX for endonasal use
- Contraindications: Tympanic membrane perforation; active purulent sinusitis; uncontrolled anticoagulation; known Hirudo allergy; immunocompromise; pediatric patients (not studied)
Arzneimittelwechselwirkungen
- Anticoagulants/antiplatelets: Additive bleeding. Relative contraindication endonasal; coagulation monitoring periauricular; nasal packing available
- Nasal decongestants: Discontinue before endonasal (therapeutic for rhinitis medicamentosa)
- Antihypertensives: Monitor BP; 25/55 rhinitis patients tolerated concurrent use
- Prophylactic antibiotics: Consider fluoroquinolone/TMP-SMX for endonasal applications (Aeromonas prophylaxis)
Regulatorischer Status
No regulatory clearance exists for ENT leech applications in the US, EU, or other major jurisdictions. FDA 510(k) K040885 clearance of Hirudo verbana is limited to venous congestion in surgical flaps/replantation. All ENT applications are off-label. In Russia, hirudotherapy is included in ENT protocols at specialist clinics within the national complementary medicine framework.
Evidenzlücken und Forschungsprioritäten
No RCT exists for any ENT indication. However, ENT disease offers standardized audiometric/imaging endpoints, quantifiable blood biomarkers, and established comparators (sinus puncture, decongestant withdrawal) that make rigorous investigation feasible. ASH supports development of controlled studies for:
- Chronic SNHL (Priority 1): RCT of HT + standard care vs. standard care in vascular/neurogenic SNHL; audiometric primary endpoint; vertebrobasilar Doppler mechanistic endpoint
- Acute sinusitis (Priority 2): Non-inferiority trial vs. maxillary sinus puncture; CT clearance endpoint; procedural burden and antibiotic use secondary
- Vasomotor rhinitis (Priority 3): Controlled comparison vs. gradual decongestant withdrawal; rhinomanometry and medication-free days endpoints
- Mechanistic studies (Priority 4): SGS effects on mucosal inflammation biomarkers (IL-6, TNF-alpha, mast cell tryptase) and cochlear blood flow (gadolinium MRI or OCT angiography)
Wichtige Erkenntnisse
Largest ENT evidence: 104 SNHL patients (Zhuravsky 2000) with audiometric + preclinical histologic data. Vascular/neurogenic etiology showed strongest response.
Vasomotor rhinitis: 3-4 month sustained breathing restoration; 3/55 required medication. Recommended as therapy of choice (Krymskaya 2003).
Sinusitis: Sinus puncture avoided in 60 patients (Moskalenko 2001) — meaningful procedural sparing.
All Level IV: No RCTs, but ENT offers standardized audiometric/imaging endpoints for rigorous studies. Endonasal risks (migration, hematoma, 9.1% allergy) require specialized training.
Verwandte Ressourcen
Klinische Fachgebiete
Alle 14 Fachgebiete im Überblick.
Neurologie
Verwandte neurovaskuläre Anwendungen.
Augenheilkunde
Geteilte mikrozirkulatorische Mechanismen.
Hirudin und gerinnungshemmende Proteine
Zentraler gerinnungshemmender Mechanismus.
Alle Indikationen
Vollständige Indikationsliste mit Evidenzstufen.